AffyImmune Therapeutics

AffyImmune is realizing the potential of cancer immunotherapy by extending the anticancer activity of CAR T-cell therapy to solid tumors. AffyImmune's "Tune & Track" platform fine-tunes the affinity of CAR T cells to reduce toxicity and prolong CAR T-cell lifespan while allowing for in vivo monitoring through a proprietary tracking system. AffyImmune's core focus is on developing CAR T cells that can effectively treat solid tumors, which account for 90% of all cancer-related deaths. Our lead compound is currently recruiting patients for a Phase I clinical trial in patients with anaplastic or refractory thyroid cancer.